Integra LifeSciences announced initial surgeries performed with the Integra® XT Revision Total Ankle Replacement system, which represents one of the first FDA-cleared devices indicated specifically for revision arthroplasty.
Available in the U.S., Integra XT is implanted using an anterior surgical approach and features:
- An augmented, posterior sloped talus, which addresses subsidence by rebuilding posterior talar height.
- An anatomic shape that mimics the natural kinematics of the ankle, designed to promote a more normal gait and better overall post-op function.
Additionally, the Integra XT system can be used to revise any commercially available primary total ankle system. It received FDA 510(k) clearance in 2016 as the Salto XT; Integra had acquired U.S. rights to the system from Tornier in 2015.
As noted in THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT®, companies like Integra that have knowledge of the foot and ankle trauma space are expanding in the faster-growing total ankle markets, seeing them as complementary to their R&D efforts and established surgeon relationships.
For the nine months ended September 30, 2018, Integra posted orthopaedic revenue of $71.2MM, -2.8% vs. 2017, with joint recon extremities revenue reaching $27.6MM, up 2.4% from the prior year, and trauma device revenue totaling $43.7MM, -5.8%.
Growth in U.S. total ankle and shoulder product lines has not been enough to offset a decline in the lower extremity trauma portfolio. Leadership stated an expectation for improved performance in 2019, aided by new products like the XT ankle revision system and the Panta II fusion nail.
*Image courtesy of Integra LifeSciences